Definitive Healthcare, which provides a healthcare intelligence platform for go-to-market sales strategies, raised $420 million by offering 15.6 million shares at $27, above the upwardly revised range of $24 to $26. The company originally planned to offer 15.6 million shares at $21 to $24, before raising the range on Monday.
Definitive Healthcare states that it is a leading provider of healthcare commercial intelligence, offering a platform leveraged by functional groups including sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. The company served over 2,600 customers as of June 30, 2021, which include biopharmaceutical and medical device companies, Healthcare Information Technology companies, healthcare providers, and other diversified companies seeking commercial success in the healthcare ecosystem.
Definitive Healthcare plans to list on the Nasdaq under the symbol DH. Goldman Sachs, J.P. Morgan, Morgan Stanley, Barclays, Credit Suisse, and Deutsche Bank acted as joint bookrunners on the deal.
